Study identifier:RDEA594-125
ClinicalTrials.gov identifier:NCT01744379
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of Lesinurad in Healthy Male Japanese Subjects
Gout
Phase 1
Yes
Lesinurad, Placebo
Male
40
Interventional
20 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jun 2013 by Ardea Biosciences, Inc.
Ardea Biosciences, Inc.
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 200 mg lesinurad 200 mg lesinurad or placebo fasted and fed | - |
Experimental: 400 mg lesinurad 400 mg lesinurad or placebo fasted and fed | - |
Experimental: 100 mg lesinurad 100 mg lesinurad or placebo fasted and fed | - |
Experimental: 50 mg lesinurad 50 mg lesinurad or placebo fasted and fed | - |
Experimental: 600 mg lesinurad 600 mg lesinurad or placebo fasted and fed | - |